<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=iso-8859-1"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:"Calibri Light";
panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:"Segoe UI";
panose-1:2 11 5 2 4 2 4 2 2 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Times New Roman",serif;
font-weight:bold;}
h2
{mso-style-priority:9;
mso-style-link:"Heading 2 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:18.0pt;
font-family:"Times New Roman",serif;
font-weight:bold;}
h3
{mso-style-priority:9;
mso-style-link:"Heading 3 Char";
margin-top:2.0pt;
margin-right:0cm;
margin-bottom:0cm;
margin-left:0cm;
margin-bottom:.0001pt;
page-break-after:avoid;
font-size:12.0pt;
font-family:"Calibri Light",sans-serif;
color:#1F4D78;
mso-fareast-language:EN-US;
font-weight:normal;}
h5
{mso-style-priority:9;
mso-style-link:"Heading 5 Char";
margin-top:2.0pt;
margin-right:0cm;
margin-bottom:0cm;
margin-left:0cm;
margin-bottom:.0001pt;
page-break-after:avoid;
font-size:11.0pt;
font-family:"Calibri Light",sans-serif;
color:#2E74B5;
mso-fareast-language:EN-US;
font-weight:normal;}
h6
{mso-style-priority:9;
mso-style-link:"Heading 6 Char";
margin-top:2.0pt;
margin-right:0cm;
margin-bottom:0cm;
margin-left:0cm;
margin-bottom:.0001pt;
page-break-after:avoid;
font-size:11.0pt;
font-family:"Calibri Light",sans-serif;
color:#1F4D78;
mso-fareast-language:EN-US;
font-weight:normal;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
{mso-style-priority:99;
mso-style-link:"Body Text Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;
mso-fareast-language:EN-US;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
{mso-style-priority:11;
mso-style-link:"Subtitle Char";
margin-top:0cm;
margin-right:0cm;
margin-bottom:8.0pt;
margin-left:0cm;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
color:#5A5A5A;
letter-spacing:.75pt;
mso-fareast-language:EN-US;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
address
{mso-style-priority:99;
mso-style-link:"HTML Address Char";
margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman",serif;
font-style:italic;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0cm;
margin-right:0cm;
margin-bottom:8.0pt;
margin-left:36.0pt;
mso-add-space:auto;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
{mso-style-priority:34;
mso-style-type:export-only;
margin-top:0cm;
margin-right:0cm;
margin-bottom:0cm;
margin-left:36.0pt;
margin-bottom:.0001pt;
mso-add-space:auto;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
{mso-style-priority:34;
mso-style-type:export-only;
margin-top:0cm;
margin-right:0cm;
margin-bottom:0cm;
margin-left:36.0pt;
margin-bottom:.0001pt;
mso-add-space:auto;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
{mso-style-priority:34;
mso-style-type:export-only;
margin-top:0cm;
margin-right:0cm;
margin-bottom:8.0pt;
margin-left:36.0pt;
mso-add-space:auto;
line-height:105%;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
span.HTMLAddressChar
{mso-style-name:"HTML Address Char";
mso-style-priority:99;
mso-style-link:"HTML Address";
font-family:"Times New Roman",serif;
mso-fareast-language:EN-ZW;
font-style:italic;}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Times New Roman",serif;
mso-fareast-language:EN-ZW;
font-weight:bold;}
span.Heading2Char
{mso-style-name:"Heading 2 Char";
mso-style-priority:9;
mso-style-link:"Heading 2";
font-family:"Times New Roman",serif;
mso-fareast-language:EN-ZW;
font-weight:bold;}
span.Heading3Char
{mso-style-name:"Heading 3 Char";
mso-style-priority:9;
mso-style-link:"Heading 3";
font-family:"Calibri Light",sans-serif;
color:#1F4D78;}
span.Heading5Char
{mso-style-name:"Heading 5 Char";
mso-style-priority:9;
mso-style-link:"Heading 5";
font-family:"Calibri Light",sans-serif;
color:#2E74B5;
mso-fareast-language:EN-US;}
span.Heading6Char
{mso-style-name:"Heading 6 Char";
mso-style-priority:9;
mso-style-link:"Heading 6";
font-family:"Calibri Light",sans-serif;
color:#1F4D78;
mso-fareast-language:EN-US;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
span.BodyTextChar
{mso-style-name:"Body Text Char";
mso-style-priority:99;
mso-style-link:"Body Text";
font-family:"Times New Roman",serif;}
span.SubtitleChar
{mso-style-name:"Subtitle Char";
mso-style-priority:11;
mso-style-link:Subtitle;
font-family:"Calibri",sans-serif;
color:#5A5A5A;
letter-spacing:.75pt;}
p.pb15, li.pb15, div.pb15
{mso-style-name:pb15;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.editor, li.editor, div.editor
{mso-style-name:editor;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.lastupdate, li.lastupdate, div.lastupdate
{mso-style-name:lastupdate;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.insinstorydvcaption, li.insinstorydvcaption, div.insinstorydvcaption
{mso-style-name:ins_instory_dv_caption;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.gray-dark, li.gray-dark, div.gray-dark
{mso-style-name:gray-dark;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.font--body, li.font--body, div.font--body
{mso-style-name:font--body;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.metadatabyline, li.metadatabyline, div.metadatabyline
{mso-style-name:metadata__byline;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.update-time, li.update-time, div.update-time
{mso-style-name:update-time;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.zn-bodyparagraph, li.zn-bodyparagraph, div.zn-bodyparagraph
{mso-style-name:zn-body__paragraph;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.c-readmore, li.c-readmore, div.c-readmore
{mso-style-name:c-readmore;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.text-center, li.text-center, div.text-center
{mso-style-name:text-center;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.image-caption, li.image-caption, div.image-caption
{mso-style-name:image-caption;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.chartsubtitle, li.chartsubtitle, div.chartsubtitle
{mso-style-name:chart__subtitle;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
p.chartsource, li.chartsource, div.chartsource
{mso-style-name:chart__source;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman",serif;}
span.EmailStyle45
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:windowtext;}
span.style30
{mso-style-name:style30;}
span.updated-wrap
{mso-style-name:updated-wrap;}
span.updated-text
{mso-style-name:updated-text;}
span.vjs-control-text
{mso-style-name:vjs-control-text;}
span.vjs-current-time-display
{mso-style-name:vjs-current-time-display;}
span.vjs-duration-display
{mso-style-name:vjs-duration-display;}
span.link600907a1
{mso-style-name:link__600907a1;}
span.pricechangea4e5ebde
{mso-style-name:pricechange__a4e5ebde;}
span.percentchange4644dd7b
{mso-style-name:percentchange__4644dd7b;}
span.nenh5bclitmmlhqori6r
{mso-style-name:nenh5bclitmmlhq_ori6r;}
span.z-TopofFormChar
{mso-style-name:"z-Top of Form Char";
mso-style-priority:99;
mso-style-link:"z-Top of Form";
font-family:"Arial",sans-serif;
display:none;}
span.3vdg7tz3nbnbjk7gdr2y2
{mso-style-name:_3vdg7tz3nbnbjk7gdr2y2_;}
span.2ml6cep2ydeajtymouc70a
{mso-style-name:_2ml6cep2ydeajtymouc70a;}
span.z-BottomofFormChar
{mso-style-name:"z-Bottom of Form Char";
mso-style-priority:99;
mso-style-link:"z-Bottom of Form";
font-family:"Arial",sans-serif;
display:none;}
span.EmailStyle62
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle63
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle64
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.black
{mso-style-name:black;}
span.fs11
{mso-style-name:fs11;}
span.bigfont
{mso-style-name:bigfont;}
span.EmailStyle68
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.pst-byli
{mso-style-name:pst-by_li;}
span.pst-bylnk
{mso-style-name:pst-by_lnk;}
span.trcrboxheaderspan
{mso-style-name:trc_rbox_header_span;}
span.video-label
{mso-style-name:video-label;}
span.trcinlinedetailspacer
{mso-style-name:trc_inline_detail_spacer;}
span.branding
{mso-style-name:branding;}
span.css-128nlh6
{mso-style-name:css-128nlh6;}
span.txtcntnr
{mso-style-name:txtcntnr;}
span.addtxt
{mso-style-name:add__txt;}
span.cmtbtn
{mso-style-name:cmt_btn;}
span.author-name
{mso-style-name:author-name;}
span.font--meta-text
{mso-style-name:font--meta-text;}
span.font-xxxs
{mso-style-name:font-xxxs;}
span.gray
{mso-style-name:gray;}
span.font-bold
{mso-style-name:font-bold;}
span.EmailStyle84
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.metadatabylineauthor
{mso-style-name:metadata__byline__author;}
span.cdheadline-text
{mso-style-name:cd__headline-text;}
span.elstoryelementheader
{mso-style-name:el__storyelement__header;}
span.c-bylineby
{mso-style-name:c-byline__by;}
span.c-bylinename
{mso-style-name:c-byline__name;}
span.c-bylinesource
{mso-style-name:c-byline__source;}
span.c-videodata
{mso-style-name:c-video__data;}
span.c-videotitle
{mso-style-name:c-video__title;}
span.c-captiondesc
{mso-style-name:c-caption__desc;}
span.sr-only
{mso-style-name:sr-only;}
span.c-fontsizersymbol
{mso-style-name:c-fontsizer__symbol;}
span.EmailStyle96
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle97
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.caas-attr-meta-separator
{mso-style-name:caas-attr-meta-separator;}
span.EmailStyle99
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.updated-date
{mso-style-name:updated-date;}
span.custom-caption
{mso-style-name:custom-caption;}
span.ie-custom-caption
{mso-style-name:ie-custom-caption;}
span.EmailStyle103
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle104
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle105
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle106
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle107
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle108
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle111
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:293605793;
mso-list-template-ids:324185034;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0cm;}
ul
{margin-bottom:0cm;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-ZW link="#0563C1" vlink="#954F72"><div class=WordSection1><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=919 style='width:689.55pt;border-collapse:collapse'><tr><td width=914 colspan=4 valign=top style='width:685.15pt;border:solid white 1.0pt;border-bottom:none;padding:0cm 5.4pt 0cm 5.4pt'></td><td width=6 style='width:4.4pt;border:none;border-top:solid white 1.0pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=914 colspan=4 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='text-indent:33.35pt;line-height:105%'><a href="https://bullszimbabwe.com/"><span style='font-family:"Verdana",sans-serif;color:windowtext;mso-fareast-language:EN-ZW;text-decoration:none'><img border=0 width=246 height=120 id="_x0000_i1028" src="cid:image001.png@01D6FBBC.CB8E91B0" alt="cid:image001.png@01D6FBBC.CB8E91B0"></span></a><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=914 colspan=4 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><a href="http://www.bullszimbabwe.com"><span style='text-decoration:none'>Bullszimbabwe.com </span></a> <a href="mailto:info@bulls.co.zw?subject=View%20and%20Comments"><span style='text-decoration:none'>Views & Comments</span></a> <a href="https://bullszimbabwe.com/category/blogs/bullish-thoughts/"><span style='text-decoration:none'>Bullish Thoughts</span></a> <a href="http://www.twitter.com/BullsBears2010"><span style='text-decoration:none'>Twitter</span></a> <a href="https://www.facebook.com/BullsBearsZimbabwe"><span style='text-decoration:none'>Facebook</span></a> <a href="http://www.linkedin.com/pub/bulls-n-bears-zimbabwe/57/577/72"><span style='text-decoration:none'>LinkedIn</span></a> <a href="https://chat.whatsapp.com/CF6wllAfScU9Wr6dXxoQnO"><span style='text-decoration:none'>WhatsApp</span></a> <a href="mailto:info@bulls.co.zw?subject=Unsubscribe"><span style='text-decoration:none'>Unsubscribe</span></a><o:p></o:p></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=914 colspan=4 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoSubtitle style='margin-left:32.1pt;text-indent:7.5pt;line-height:105%'><span class=style30><b><span style='font-family:"Verdana",sans-serif;color:windowtext'><o:p> </o:p></span></b></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> </span><span style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td></tr><tr><td width=914 colspan=4 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><span class=style30><b><span lang=EN-US style='font-family:"Verdana",sans-serif;color:#1F497D'>Coronavirus Global Updates, Feb 21 ::::Global Vaccines Reach 202 Million , Philippines Confirms 18 Additional Cases of U.K. Variant and Russia Reports Lowest New Cases Since Oct. 9</span></b></span><b><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></b></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=914 colspan=4 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><span class=style30><b><span style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></b></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> </span><span style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td></tr><tr style='height:3.0pt'><td width=914 colspan=4 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:3.0pt'><p class=MsoNormal style='line-height:105%'><span style='font-family:"Verdana",sans-serif'><a href="https://www.nicozdiamond.co.zw/"><span style='color:windowtext;mso-fareast-language:EN-ZW;text-decoration:none'><img border=0 width=883 height=272 id="Picture_x0020_6" src="cid:image002.png@01D70828.70EB93C0" alt="cid:image002.png@01D70828.70EB93C0"></span><span style='color:windowtext;text-decoration:none'> </span></a><span class=style30><b><o:p></o:p></b></span></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:3.0pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> </span><span style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td></tr><tr style='height:10.05pt'><td width=914 colspan=4 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:10.05pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:10.05pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr style='height:10.05pt'><td width=914 colspan=4 rowspan=3 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.05pt'><h1 style='line-height:33.75pt;background:white'><span lang=EN-US style='font-size:11.0pt;font-family:"Verdana",sans-serif;mso-fareast-language:EN-US'>Zimbabwe COVID19 Update<o:p></o:p></span></h1><p class=MsoNormal style='background:white'><span style='font-size:11.5pt;font-family:"Segoe UI",sans-serif;color:#0F1419'>COVID-19 update: As at 20 February 2021, Zimbabwe had 35 768 confirmed cases, including 32 096 recoveries and 1 432 deaths.</span><span style='font-family:"Verdana",sans-serif;color:#1F497D'><br><br></span><span style='font-family:"Verdana",sans-serif;color:#1F497D;mso-fareast-language:EN-ZW'><img border=0 width=603 height=837 id="Picture_x0020_9" src="cid:image004.jpg@01D70850.2BAB9530" alt=Image></span><span style='font-family:"Verdana",sans-serif;color:#1F497D'> </span><span style='font-family:"Verdana",sans-serif;mso-fareast-language:EN-ZW'><img border=0 width=32 height=32 id="Rectangle_x0020_1" src="cid:image006.png@01D70789.BF2A3F90" alt=Image></span><span style='font-family:"Verdana",sans-serif;color:#1F497D'><o:p></o:p></span></p><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:15.0pt;margin-left:0cm;background:white;vertical-align:baseline'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black;letter-spacing:-.3pt'><br></span><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black;letter-spacing:-.3pt'>Global Vaccines Top 202 Million; Russia Cases Slow: Virus Update<br></span><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black;font-weight:normal'>Serbia added a fourth vaccine to its program by taking delivery from AstraZeneca Plc while Australia kicked off its program on Sunday and South Korea will start rolling out vaccinations from Friday. The U.K. will offer doses to <a href="https://www.bloomberg.com/news/articles/2021-02-20/u-k-speeds-vaccine-program-to-offer-all-adults-shot-by-july-31" target="_blank" title="U.K. Speeds Vaccine Program to Offer All Adults Shot by July 31"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>all adults</span></a> by the end of July as the government beefs up efforts to contain one of the world’s worst outbreaks.</span><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'><o:p></o:p></span></h1><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Russia reported its lowest new cases since October while Johnson & Johnson’s Covid-19 vaccine is expected to be given European Union approval in the next two to four weeks. Fujifilm Holdings Corp. plans to restart clinical trials of Avigan in April, Nikkei reported.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=key-developments><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>German Contagion Rate Rises to Highest in More Than a Week <br></span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Germany’s seven-day Covid-19 incidence rate per 100,000 people inched up on Sunday to the highest level in over a week -- the latest evidence that a steady decline since a peak before Christmas has ground to a halt.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>The rate rose to 60.2, the highest level since Feb. 12, according to data from the RKI public-health institute. The increase comes as pressure grows on the government to lay out a reopening plan, even amid concerns about fast-spreading variants. The government has said a rate of 50 or below is manageable and may allow a cautious easing of lockdown restrictions including shuttered schools and non-essential stores.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=russia-reports-lowest-new-cases-since-oct-9-412-pm-hk><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Russia Reports Lowest New Cases Since Oct. 9</span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'> <br>Russia reported 12,742 new cases of Covid-19, the lowest since Oct. 9, according to the government’s virus response center. Total cases have reached 4.16 million.<o:p></o:p></span></h3><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>The data show 417 people died in the past day, pushing the death toll to 83,293 since the start of the pandemic. Federal statistics show the number of deaths linked to Covid-19 last year was nearly three times higher than the government response center reported.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=serbia-adds-fourth-vaccine-with-astrazeneca-delivery-348-pm-><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Serbia Adds Fourth Vaccine With AstraZeneca Delivery</span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'> <br>Serbia received its first delivery of AstraZeneca shots on Sunday, adding a fourth vaccine to its program after already importing nearly 2 million doses from Pfizer-BioNTech, China’s Sinopharm as well as the Russian Sputnik V.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Around 756,000 people in the Balkan nation of 7 million have been vaccinated, including almost 500,000 with two doses, President Aleksandar Vucic told reporters at Belgrade airport where the shipment was delivered.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Serbia donated 2,000 shots to Montenegro as its smaller neighbor kicked off inoculations on Saturday. The Adriatic country’s population is around 650,000.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=iran-says-barakat-vaccine-90-effective-against-coronavirus-320-pm-hk><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Iran Says Barakat Vaccine 90% Effective Against Coronavirus</span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'> <br>Iran’s homemade COVIran Barakat vaccine for Covid-19 is 90% effective against the virus, the state-run Islamic Republic News Agency reported.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>The vaccine is currently in its second stage of human trials and officials plan to have over 20,000 people inoculated by the vaccine by May 20, according to the semi-official Young Journalists Club.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=philippines-confirms-18-additional-cases-of-uk-variant-319-pm-hk><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Philippines Confirms 18 Additional Cases of U.K. Variant</span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'> <br>The Philippines confirmed 18 additional cases of the coronavirus variant first found in the U.K., bringing the total of such cases to 62 as of Sunday, according to the Department of Health. Thirteen of the cases are returning overseas Filipino workers who entered the country between January 3-27, and all of these cases are now tagged as recovered, it said.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>The country also detected N501Y and E484K mutations in three samples from confirmed Covid-19 patients in its central Visayas islands, the Health Department also said. “Investigation is now underway to aid in curbing transmission,” it said in a statement.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=italian-governors-to-push-central-government-for-more-vaccines-301-pm-hk><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Italian Governors to Push Central Government for More Vaccines</span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'> <br>Regional governors will request the Italian government increase efforts to find more vaccine doses as they also seek new parameters for the tightening restrictions in pars of the country.<o:p></o:p></span></h3><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>The requests were outlined in a joint statement after the regional leaders met to discuss ways to deal with the pandemic.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=switzerland-may-resell-its-astrazeneca-doses-amid-efficacy-concern-nzz-says-247-pm-hk><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Switzerland May Resell its AstraZeneca Doses Amid Efficacy Concern, NZZ Says</span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'> <br>Switzerland may resell its 5.3 million doses of AstraZeneca’s vaccine amid questions over its efficacy, Neue Zürcher Zeitung reported Sunday.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>There are considerations about passing the material on, said Nora Kronig, the deputy director of the Federal Office of Public Health. The country’s regulator, Swissmedic, has not yet approved the shot and is requesting more data from a trial underway in North and South America.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=south-korea-to-use-astrazeneca-vaccine-from-friday-228-pm-hk><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>South Korea to Use AstraZeneca Vaccine From Friday</span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'> <br>South Korea will commence its vaccinations on Friday using AstraZeneca’s shot, Prime Minister Chung Sye-kyun said Sunday in a televised briefing.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Pfizer’s vaccine will be used to inoculate medical personnel from Saturday, a day after enough supplies to treat 117,000 people are due to arrive in the country, he said.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=malaysia-to-start-covid19-vaccinations-ahead-of-plan-star-reports-135-pm-hk><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Malaysia to Start Covid-19 Vaccinations Ahead of Plan, Star Reports</span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'> <br>Malaysia will start its Covid-19 vaccination program on Feb. 24, two days ahead of schedule, The Star reported, citing Science, Technology and Innovation Minister Khairy Jamaluddin after the first batch of vaccines arrived on Sunday.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Prime Minister Muhyiddin Yassin will be the first to receive the vaccine, followed by Health Director-General Noor Hisham Abdullah, according to the report. The first batch of 312,390 Pfizer-BioNTech vaccines will be administered to over 271,000 frontline workers, of whom 57.3% are medical personnel and 42.7% non-medical staff, it said.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=global-vaccines-reach-202-million-946-am-hk><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Global Vaccines Reach 202 Million <br></span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>More than 202 million vaccine doses have been administered around the world, according to data compiled by the Bloomberg Vaccine Tracker, just over two months after the first shots went into arms.<o:p></o:p></span></h3><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Vaccinations are underway in at least 88 countries, including nations in Africa, Asia, Europe and North and South America. While the doses given so far are only a fraction of what will be needed to cover the globe, about 6.35 million doses a day are being administered.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=fujifilm-plans-to-resume-avigan-trial-in-april-nikkei-says-853-am-hk><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Fujifilm Plans to Resume Avigan Trial in April, Nikkei Says <br></span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Fujifilm Holdings Corp. plans to restart the clinical trials of Avigan in April, the Nikkei newspaper reported without citing anyone.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Japanese regulators in December postponed a decision to approve the company’s antiviral drug to treat Covid-19, asking the company for more data. The decision to approve could come after October when the clinical trials are seen to be completed, and upon review by the government, the report said.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=australia-starts-vaccinations-729-am-hk><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Australia Starts Vaccinations <br></span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Australia’s vaccination program started on Sunday, with Prime Minister Scott Morrison <a href="https://www.bloomberg.com/news/articles/2021-02-20/australia-starts-covid-vaccination-pm-among-first-to-get-a-shot" target="_blank" title="Australia Starts Covid Vaccination; PM Among First to Get a Shot" id=107494><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>among the first</span></a> to get an injection.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Morrison and the nation’s chief medical and nursing officers will be among a small group receiving the vaccination to help build public confidence in its safety, Health Minister Greg Hunt said on ABC television. The broader rollout will start on Monday.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=extrump-official-says-grave-mask-misstep-cost-us-723-am-hk><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Ex-Trump Official Says Grave ‘Mask Misstep’ Cost U.S.</span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'> <br>The Trump administration erred in not providing guidance on the effectiveness of face masks early in the pandemic, said Matthew Pottinger, former deputy national security adviser.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>“The mask misstep cost us dearly. It was the one tool that was widely available, at least homemade, you know, cotton masks were widely available,” Pottinger said in an interview with CBS that will run in full on Sunday. “It was the one effective, widely available tool that we had in the arsenal to deal with this...It was a grave misstep.”<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Surveys in 2020 showed that supporters of Donald Trump, and Republicans in general, were less likely than Democrats to “mask up” to prevent the spread of Covid-19.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=uk-to-offer-all-adults-shots-by-july-535-pm-ny><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>U.K. to Offer All Adults Shots by July <br></span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>The U.K. will significantly accelerate its vaccination program, offering shots to <a href="https://www.bloomberg.com/news/articles/2021-02-20/u-k-speeds-vaccine-program-to-offer-all-adults-shot-by-july-31" target="_blank" title="U.K. Speeds Vaccine Program to Offer All Adults Shot by July 31"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>all adults</span></a> by the end of July and everyone over 50 by mid-April as the government beefs up efforts to contain one of the world’s worst outbreaks of the coronavirus.<o:p></o:p></span></h3><p style='margin:0cm;margin-bottom:.0001pt;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Prime Minister Boris Johnson will set out the new targets on Monday when he reveals his “<span style='border:none windowtext 1.0pt;padding:0cm'>roadmap</span>” to easing lockdown restrictions. It is the first time the government has given a firm target for when it expects to offer all adults their initial dose, having previously said it hoped to do so by autumn. The previous target set for over-50s was the end of May.<br><br><o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=pfizer-vaccine-prevents-99-of-deaths-israel-ministry-337-pm-ny><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Pfizer Vaccine Prevents 99% of Deaths: Israel Ministry <br></span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>The vaccine developed by Pfizer Inc. and BioNTech SE is 98.9% effective at preventing Covid-19 deaths, according to Israel’s Health Ministry.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Protection was highest two weeks after getting the second shot, while effectiveness was at 94.5% a week after the second dose, according to data the ministry released on Saturday.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>The rates of preventing morbidity, symptomatic cases and hospitalization were all higher than 95% two weeks past the second jab, the data show.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=secondshot-crunch-leaves-many-without-full-immunizations-218-pm-ny><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Second-Shot Crunch Leaves Many Without Full Immunizations <br></span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Almost a month after U.S. vaccination campaigns ramped <span style='border:none windowtext 1.0pt;padding:0cm'>up to</span> give Covid-19 shots to more than a million people a day, their second doses are coming due, <a href="https://www.bloomberg.com/news/articles/2021-02-20/second-shot-crunch-leaves-many-without-complete-immunizations" target="_blank" title="Second-Shot Crunch Leaves Many Without Complete Immunizations"><span style='color:black;border:none windowtext 1.0pt;padding:0cm;text-decoration:none'>straining state rollouts</span></a> and and leaving some without complete immunizations.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>In Texas alone, almost 6,000 people were overdue for their second shots in early February. Washington state officials said earlier this week that some mass vaccination clinics would only deliver follow-up doses. And a Michigan hospital system canceled last-dose appointments for the past week after its supply was reduced.<o:p></o:p></span></p><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>“For the first six weeks of this program or so, we were only giving first shots, and now we have to kind of pay the piper,” said Eric Toner, a senior scholar at the Johns Hopkins Center for Health Security.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline'><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Germany Expects J&J Vaccine Approval in 2-4 Weeks <br></span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>A rival shot developed by CureVac NV will take longer and may get the green light in April or May, Spahn said during a virtual discussion on Germany’s vaccination program.<o:p></o:p></span></h3><p style='mso-margin-top-alt:22.5pt;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Spahn added that Germany would have no problem using the Russian Sputnik V vaccine as long as data and testing conformed with EU standards.<o:p></o:p></span></p><h3 style='mso-margin-top-alt:9.25pt;margin-right:0cm;margin-bottom:9.25pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit' id=uk-care-home-restrictions-relaxed-6-am-ny><b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>U.K. Care Home Restrictions Relaxed</span></b><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'> <br>In news that will be welcomed by families who have been unable to see their relatives in care homes for months, chosen visitors will be able to meet indoors and hold hands, Health Secretary Matt Hancock confirmed in a statement today.</span><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'><o:p></o:p></span></h3><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline;font-variant:inherit;font-weight:inherit;font-stretch: inherit;line-height:inherit'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:black'>Hancock said the proposed easing of strict care home measures is the “first step to getting back to where we want to be.” Hancock’s statement comes ahead of Prime Minister Boris Johnson revealing his “road map” for bringing the nation out of lockdown on Monday.<o:p></o:p></span></p><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:22.5pt;margin-left:0cm;background:white;vertical-align:baseline'><span style='font-size:11.0pt;font-family:"Verdana",sans-serif;color:#1F497D'><o:p> </o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:10.05pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:10.05pt'><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:10.05pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:10.05pt'><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:10.05pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:10.05pt'><td width=914 colspan=4 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.05pt'><p class=MsoNormal style='mso-margin-top-alt:auto;margin-left:36.0pt;line-height:115%;background:white'><b><span style='font-family:"Verdana",sans-serif;mso-fareast-language:EN-ZW'><o:p> </o:p></span></b></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:10.05pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr><td width=914 colspan=4 style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p><p class=MsoNormal style='line-height:105%'><strong><span lang=EN-US style='font-family:"Verdana",sans-serif'>INVESTORS DIARY 2021</span></strong><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr style='height:3.25pt'><td width=217 style='width:163.0pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='text-indent:12.6pt;line-height:105%'><b><span lang=EN-US style='font-family:"Verdana",sans-serif'>Company</span></b><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td><td width=201 style='width:150.95pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><b><span lang=EN-US style='font-family:"Verdana",sans-serif'>Event</span></b><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td><td width=304 style='width:228.2pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><b><span lang=EN-US style='font-family:"Verdana",sans-serif'>Venue</span></b><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td><td width=191 valign=bottom style='width:143.0pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><b><span lang=EN-US style='font-family:"Verdana",sans-serif'>Date & Time</span></b><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p></o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr style='height:3.25pt'><td width=217 valign=top style='width:163.0pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=201 style='width:150.95pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=304 style='width:228.2pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=191 valign=top style='width:143.0pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='margin-left:72.0pt;text-indent:-72.0pt;line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:3.25pt'><td width=217 valign=top style='width:163.0pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=201 style='width:150.95pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=304 style='width:228.2pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=191 valign=top style='width:143.0pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='margin-left:72.0pt;text-indent:-72.0pt;line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:3.25pt'><td width=419 colspan=2 valign=top style='width:313.95pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#D9D9D9;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><b><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Companies under Cautionary<o:p></o:p></span></b></p></td><td width=304 style='width:228.2pt;border:none;border-right:solid white 1.0pt;background:#D9D9D9;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><b><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></b></p></td><td width=191 valign=bottom style='width:143.0pt;border:none;border-right:solid white 1.0pt;background:#D9D9D9;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><b><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></b></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:3.25pt'><td width=419 colspan=2 valign=top style='width:313.95pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=304 style='width:228.2pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=191 valign=bottom style='width:143.0pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:3.25pt'><td width=419 colspan=2 valign=top style='width:313.95pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>ART<o:p></o:p></span></p></td><td width=304 style='width:228.2pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>PPC<o:p></o:p></span></p></td><td width=191 valign=bottom style='width:143.0pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Dairibord<o:p></o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr style='height:3.25pt'><td width=419 colspan=2 valign=top style='width:313.95pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Starafrica<o:p></o:p></span></p></td><td width=304 style='width:228.2pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Fidelity<o:p></o:p></span></p></td><td width=191 valign=bottom style='width:143.0pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Turnall<o:p></o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr style='height:3.25pt'><td width=419 colspan=2 valign=top style='width:313.95pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Medtech<o:p></o:p></span></p></td><td width=304 style='width:228.2pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Zimre<o:p></o:p></span></p></td><td width=191 valign=bottom style='width:143.0pt;border:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt;height:3.25pt'><p class=MsoBodyText style='margin:0cm;margin-bottom:.0001pt;line-height:105%'><span lang=EN-US style='font-size:11.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Nampak Zimbabwe<o:p></o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm;height:3.25pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td></tr><tr><td width=914 colspan=4 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#1F497D;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><i><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></i></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=914 colspan=4 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#1F497D;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><i><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif;color:white'>DISCLAIMER: This report has been prepared by Bulls ‘n Bears, a division of Faith Capital (Pvt) Ltd for general information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities. The information contained in this report has been compiled from sources believed to be reliable, but no representation or warranty is made or guarantee given as to its accuracy or completeness. All opinions expressed and recommendations made are subject to change without notice. Securities or financial instruments mentioned herein may not be suitable for all investors. Securities of emerging and mid-size growth companies typically involve a higher degree of risk and more volatility than the securities of more established companies. Neither Faith Capital nor any other member of Bulls ‘n Bears nor any other person, accepts any liability whatsoever for any loss howsoever arising from any use of this report or its contents or otherwise arising in connection therewith. Recipients of this report shall be solely responsible for making their own independent investigation into the business, financial condition and future prospects of any companies referred to in this report. Other Indices quoted herein are for guideline purposes only and sourced from third parties.</span></i><i><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p></o:p></span></i></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=914 colspan=4 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><i><span lang=EN-GB style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></i></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=914 colspan=4 valign=top style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'>(c) 2021 <b>Web</b>:</span><span style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'><a href="http://www.bullszimbabwe.com"><span lang=EN-US style='color:windowtext;text-decoration:none'> www.bullszimbabwe.com </span></a></span><b><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'>Email:</span></b><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'> </span><span style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'><a href="mailto:info@bulls.co.zw"><span lang=EN-US style='color:windowtext;text-decoration:none'>info@bulls.co.zw</span></a></span><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'> <b>Tel:</b> +263 4 2927658 <b>Cell:</b> +263 77 344 1674<o:p></o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr><tr><td width=914 colspan=4 valign=bottom style='width:685.15pt;border-top:none;border-left:solid white 1.0pt;border-bottom:none;border-right:solid white 1.0pt;background:#F2F2F2;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></p><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></p><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></p><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-size:8.0pt;line-height:105%;font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></td><td width=6 style='width:4.4pt;padding:0cm 0cm 0cm 0cm'><p class=MsoNormal style='line-height:105%'><span lang=EN-US style='font-family:"Verdana",sans-serif'> <o:p></o:p></span></p></td></tr></table></div><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana",sans-serif'><o:p> </o:p></span></p></div></body></html>